Posttranslational modifications of PPAR-γ: Fine-tuning the metabolic master regulator

Obesity

Volumn 17, Issue 2, 2009, Pages 213-219

  Beekum, Olivier Van ^a,b,c   Fleskens, Veerle ^a,b   Kalkhoven, Eric ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NETHERLANDS METABOLOMICS CENTRE   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL; ARTICLE; ENERGY METABOLISM; HUMAN; LIPID METABOLISM; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; UBIQUITINATION;

ANIMALS; ENERGY METABOLISM; GLUCOSE; HUMANS; LIPID METABOLISM; PHOSPHORYLATION; PPAR GAMMA; PROTEIN PROCESSING, POST-TRANSLATIONAL; UBIQUITINATION;

EID: 58849102970     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2008.473     Document Type: Article

References (70)

1. Lehrke M, Lazar MA. The many faces of PPARgamma. Cell 2005;123:993-999.
2. Knouff C, Auwerx J. Peroxisome proliferatoractivated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev 2004;25: 899-918.
3. Nolte RT, Wisely GB, Westin S et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 1998;395:137-143.
4. Guan HP, Ishizuka T, Chui PC, Lehrke M, Lazar MA. Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. Genes Dev 2005;19: 453-461.
5. Perissi V, Rosenfeld MG. Controlling nuclear receptors: the circular logic of cofactor cycles. Nat Rev Mol Cell Biol 2005;6:542-554.
6. Kumar R, Thompson EB. Transactivation functions of the N-terminal domains of nuclear hormone receptors: protein folding and coactivator interactions. Mol Endocrinol 2003;17:1-10.
7. Baker PRS, Lin YM, Schopfer FJ et al. Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferatoractivated receptor ligands. J Biol Chem 2005;280:42464-42475.
8. Forman BM, Tontonoz P, Chen J et al. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995;83:803-812.
9. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-1118.
10. Barak Y, Nelson MC, Ong ES et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999;4:585-595.
11. Kubota N, Terauchi Y, Miki H et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999;4:597-609.
12. Rosen ED, Sarraf P, Troy AE et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999;4:611-617.
13. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994;79:1147-1156.
14. Imai T, Takakuwa R, Marchand S et al. Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse. Proc Natl Acad Sci USA 2004;101:4543-4547.
15. Hegele RA. Lessons from human mutations in PPARgamma. Int J Obes (Lond) 2005;29(Suppl 1):S31-S35.
16. Wan Y, Chong LW, Evans RM. PPAR-gamma regulates osteoclastogenesis in mice. Nat Med 2007;13:1496-1503.
17. Castillo G, Brun RP, Rosenfield JK et al. An adipogenic cofactor bound by the differentiation domain of PPAR gamma. EMBO J 1999;18:3676-3687.
18. Hummasti S, Tontonoz P. The peroxisome proliferator-activated receptor N-terminal domain controls isotype-selective gene expression and adipogenesis. Mol Endocrinol 2006;20:1261-1275.
19. van Beekum O, Brenkman AB, Grøntved L et al. The adipogenic acetyltransferase Tip60 targets activation function 1 of PPARgamma. Endocrinology 2008;149:1840-1849.
20. Hu ED, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPAR gamma. Science 1996;274:2100-2103.
21. Tang XQ, Guilherme A, Chakladar A et al. An RNA interference-based screen identifies MAP4K4/NIK as a negative regulator of PPAR gamma, adipogenesis, and insulin-responsive hexose transport. Proc Natl Acad Sci USA 2006;103:2087-2092.
22. Camp HS, Tafuri SR. Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase. J Biol Chem 1997;272:10811-10816.
23. Reginato MJ, Krakow SL, Bailey ST, Lazar MA. Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma. J Biol Chem 1998;273:1855-1858.
24. Zhang B, Berger J, Zhou GC et al. Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma. J Biol Chem 1996;271:31771-31774.
25. Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VK. Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem 1997;272: 5128-5132.
26. Camp HS, Tafuri SR, Leff T. c-Jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor-gamma 1 and negatively regulates its transcriptional activity. Endocrinology 1999;140:392-397.
27. Werman A, Hollenberg A, Solanes G et al. Ligand-independent activation domain in the N terminus of peroxisome proliferatoractivated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin. J Biol Chem 1997;272:20230-20235.
28. Shao D, Rangwala SM, Bailey ST et al. Interdomain communication regulating ligand binding by PPAR-gamma. Nature 1998;396:377-380.
29. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998;339: 953-959.
30. Iwata M, Haruta T, Usui I et al. Pioglitazone ameliorates tumor necrosis factoralpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator-activated receptor-gamma. Diabetes 2001;50: 1083-1092.
31. Hosooka T, Noguchi T, Kotani K et al. Dok1 mediates high-fat diet-induced adipocyte hypertrophy and obesity through modulation of PPAR-gamma phosphorylation. Nat Med 2008;14:188-193.
32. Compe E, Drane P, Laurent C et al. Dysregulation of the peroxisome proliferator-activated receptor target genes by XPD mutations. Mol Cell Biol 2005;25:6065-6076.
33. Iankova I, Petersen RK, Annicotte JS et al. Peroxisome proliferator-activated receptor gamma recruits the positive transcription elongation factor b complex to activate transcription and promote adipogenesis. Mol Endocrinol 2006;20:1494-1505.
34. Zurita M, Merino C. The transcriptional complexity of the TFIIH complex. Trends Genet 2003;19:578-584.
35. Garriga J, Grana X. Cellular control of gene expression by T-type cyclin/CDK9 complexes. Gene 2004;337:15-23.
36. Yamashita D, Yamaguchi T, Shimizu M et al. The transactivating function of peroxisome proliferator-activated receptor gamma is negatively regulated by SUMO conjugation in the amino-terminal domain. Genes Cells 2004;9:1017-1029.
37. Floyd ZE, Stephens JM. Control of peroxisome proliferator-activated receptor gamma2 stability and activity by SUMOylation. Obes Res 2004;12:921-928.
38. Shimizu M, Yamashita D, Yamaguchi T, Hirose F, Osumi T. Aspects of the regulatory mechanisms of PPAR functions: analysis of a bidirectional response element and regulation by sumoylation. Mol Cell Biochem 2006;286:33-42.
39. Ohshima T, Koga H, Shimotohno K. Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO-1 modification. J Biol Chem 2004;279:29551-29557.
40. Geiss-Friedlander R, Melchior F. Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol 2007;8:947-956.
41. Yang XJ, Gregoire S. A recurrent phosphosumoyl switch in transcriptional repression and beyond. Mol Cell 2006;23:779-786.
42. Hietakangas V, Anckar J, Blomster HA et al. PDSM, a motif for phosphorylation-dependent SUMO modification. Proc Natl Acad Sci USA 2006;103:45-50.
43. Tremblay AM, Wilson BJ, Yang XJ, Giguère V. Phosphorylation- Dependent sumoylation regulates ERR-alpha and -gamma transcriptional activity through a synergy control motif. Mol Endocrinol 2007;22:570-584.
44. Lin DY, Huang YS, Jeng JC et al. Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol Cell 2006;24:341-354.
45. Lee MB, Lebedeva LA, Suzawa M et al. The DEAD-box protein DP103 (Ddx20 or Gemin-3) represses orphan nuclear receptor activity via SUMO modification. Mol Cell Biol 2005;25:1879-1890.
46. Stielow B, Sapetschnig A, Kruger I et al. Identification of SUMO-dependent chromatinassociated transcriptional repression components by a genome-wide RNAi screen. Mol Cell 2008;29:742-754.
47. Pascual G, Fong AL, Ogawa S et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005;437:759-763.
48. Ghisletti S, Huang W, Ogawa S et al. Parallel SUMOylation- dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPAR gamma. Mol Cell 2007; 25:57-70.
49. Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem 2001;70:503-533.
50. Muratani M, Tansey WP. How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol 2003;4:192-201.
51. Lonard DM, Nawaz Z, Smith CL, O'Malley BW. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol Cell 2000;5:939-948.
52. Reid G, Hubner MR, Metivier R et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 2003;11:695-707.
53. Waite KJ, Floyd ZE, Arbour-Reily P, Stephens JM. Interferon-gamma-induced regulation of peroxisome proliferator-activated receptor gamma and STATs in adipocytes. J Biol Chem 2001;276:7062-7068.
54. Christianson JL, Nicoloro S, Straubhaar J, Czech MP. Stearoyl-CoA desaturase 2 is required for peroxisome proliferator-activated receptor gamma expression and adipogenesis in cultured 3T3-L1 cells. J Biol Chem 2008;283:2906-2916.
55. Hauser S, Adelmant G, Sarraf P et al. Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. J Biol Chem 2000;275:18527-18533.
56. Floyd ZE, Stephens JM. Interferon-gamma-mediated activation and ubiquitin-proteasome-dependent degradation of PPAR gamma in adipocytes. J Biol Chem 2002;277:4062-4068.
57. Kintscher U, Hartge M, Hess K et al. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol 2008;28: 1304-1310.
58. Witze ES, Old WM, Resing KA, Ahn NG. Mapping protein post-translational modifications with mass spectrometry. Nat Methods 2007;4:798-806.
59. Rangwala SM, Rhoades B, Shapiro JS et al. Genetic modulation of PPAR gamma phosphorylation regulates insulin sensitivity. Dev Cell 2003;5:657-663.
60. Blüher M, Paschke R. Analysis of the relationship between PPAR-gamma 2 gene variants and severe insulin resistance in obese patients with impaired glucose tolerance. Exp Clin Endocrinol Diabetes 2003;111:85-90.
61. Hamer OW, Forstner D, Ottinger I et al. The Pro115Gln polymorphism within the PPAR gamma2 gene has no epidemiological impact on morbid obesity. Exp Clin Endocrinol Diabetes 2002;110:230-234.
62. Evans D, Mann WA, de HJ et al. Variation in the gene for human peroxisome proliferator activated receptor gamma (PPARgamma) does not play a major role in the development of morbid obesity. Int J Obes Relat Metab Disord 2000;24:647-651.
63. Clement K, Hercberg S, Passinge B et al. The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes. Int J Obes Relat Metab Disord 2000;24: 391-393.
64. Armoni M, Kritz N, Harel C et al. Peroxisome proliferator- activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect. J Biol Chem 2003;278: 30614-30623.
65. Tavera-Mendoza LE, Mader S, White JH. Genome-wide approaches for identification of nuclear receptor target genes. Nucl Recept Signal 2006;4:e018.
66. Mardis ER. ChIP-seq: welcome to the new frontier. Nat Methods 2007;4:613-614.
67. Ulrich HD. Mutual interactions between the SUMO and ubiquitin systems: a plea of no contest. Trends Cell Biol 2005;15: 525-532.
68. Hunter T. The age of crosstalk: phosphorylation, ubiquitination, and beyond. Mol Cell 2007;28:730-738.
69. Gervois P, Fruchart JC, Staels B. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab 2007;3: 145-156.
70. Balint BL, Nagy L. Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases. Endocr Metab Immune Disord Drug Targets 2006;6:33-43.